Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas. Preliminary results of a phase II, single-institutional trial

Clinical and Translational Oncology

Volumn 7, Issue 2, 2005, Pages 60-65

  De La Vega, Fernando Arias ^a   Domínguez Domínguez, Miguel Angel ^a   Burgaleta, Ana Manterola ^a   García, Ruth Vera ^a   Echeverría Zabalza, Maria Eugenia ^a   Mundin, Eugenio Oria ^a   López, Enrique Martínez ^a   Rojano, Pilar Romero ^a   Iture, Elena Villafranca ^a  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

Chemo radiotherapy; Head and neck cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HEAD AND NECK TUMOR; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 24344470632     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/BF02710011     Document Type: Article

References (47)

1. Vokes EE, Weichselbaum RR, Lippman S, et al. Head and neck cancer. N Engl J Med. 1993;328:184-94.
2. Paccagnell A, Orlando A, Marcniori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui tu-mori della Testa e del collo. J Natl Cancer Inst. 1994; 86:265-72.
3. Jacobs C, Makuch R. Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: A subset analysis of the Head and Neck Contracts Program. J Clin Oncol. 1990;18:838-47.
4. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. Engl J Med. 1993;328:15-20.
5. Fletcher G, Lindberg R, Hamberger H, et al. Reasons for irradiation failure in squamous cell carcinoma of the larynx. Laryngoscope. 1975;85:987-92.
6. Withers HR. Biologic basis for alterated fractionation schemes. Cancer. 1985;55:2086-96.
7. Ang KK, Peter LJ, Webwe RS, et al. Concomitant boost radiotherapy schedules in the treatment of the carcinomas of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys. 1990;19:1339-45.
8. Dische S, Saunders MI. The rationale for continuos, hy-perfractionated, accelerated radiotherapy (CHART). Int Radiat Oncol Biol Phys. 1990;19:1317-20.
9. Horiot JC, Le Fur R, ǸGuyen T, et al. Hyperfractiona-tion versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC Cooperative Group of Radiotherapy. Radiother Oncol. 1990;8:838-47
10. Fu KK, Pajak F, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation therapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;7-16.
11. Pignon JP, Bourhis J, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analy-sis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949-55.
12. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractiona-ted radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol. 2000;18:1458-64.
13. Adelstein DJ, Li Y, Adams GL, et al. Comparison os standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92-8.
14. Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: Rationale and clinical experience in patients with solid tumors. Clin Oncol. 1990;8:911-34.
15. Adelstein DJ, Saxton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results. Head & Neck. 1887;19:567-75.
16. Browman GP, Cripps C, Hodson DI, et al. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol. 1994;12:2648-53.
17. Haffty BG, Son YH, Papac R, et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale Mitomycin Randomized Trials. J Clin Oncol. 1997;15: 268-76.
18. Merlano M, Benasso M, Corvo R, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 1996;88:583-9.
19. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multi-center study. J Clin Oncol. 1998;16:1318-24.
20. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractiona-ted irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798-804.
21. Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiothe-rapy versus radiotherapy in patients with advanced na-sopharyngeal cancer: Phase III randomized intergroup study 0099. J Clin Oncol. 1998;16:1310-7
22. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst. 1999;2081-6.
23. Miller AB, Hoogstraten B, Staquet, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-14.
24. Rubin P, Constine LS, Fajardo L, Phillips T, Wasserman T. Overview: Late Effects of Normal Tissues (LENT) Scoring System. Int J Radiat Oncol Biol Phys. 1995;31: 1041-2.
25. Abitbol AA, Schawade JG, Lewin AA. Hyperfractionated radiation therapy and concurrent 5-fluorouracil, cispla-tin and mytomicin-C in head and neck carcinoma. Am J Clin Oncol. 1992;15:250-5.
26. Choi KN, Rotman M, Aziz H, et al. Locally advanced pa-ranasal sinus and nasopharynx tumors treated with hi-perfactionated radiation and concomitant infusion cis-platin. Cancer. 1991;67:2748-52.
27. Fontanesi J, Beckford NS, Lester EP, et al. Concomitant cisplatin and hyperfractionated external beam irradiation for advanced malignancy of the head and neck. Ann J Surg. 1991;162:393-6.
28. Glanzmann C, Lutolf UM. Follow up data of our pilot study on concomitant hyperfractionated radiotherapy and cisplatinum (CDDP) in patients with advanced cancer of the head and neck. Strahlenther Onkol. 1992; 168:453-6.
29. Harrison LB, Pfister DG, Shah JP, et al. Concomitant chemo-radiation therapy for advanced unresectable head and neck cancer. Int J Radiat Oncol Biol Phys. 1991; 21:703-8.
30. Vokes EE, Kies MS, Haraf DJ, et al. Concomitant chemo-radiotherapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000;18:1652-61.
31. Adelstein DJ, Saxton JP, Lavertu P, et al. Maximixing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol. 2002;20:1405-10.
32. Forastiere AA, Bellibeau JF, Goren MO, et al. Pharmaco-kinetic and toxicity evaluation of five-day continuos infusion versus intermittent bolus cis-diamminedichloro-platinum (II) in head and neck cancer patients. Cancer Res. 1988;48:3869-74.
33. Arias F, Domínguez MA, Illarramendi JJ, et al. Split hi-perfractionated accelerated radiation therapy and concomitant cisplatin for locally advanced head and neck carcinomas: A preliminary report. Int J Radiat Oncol. 1995;33:675-82.
34. Arias F, Vera R, Domínguez MA, et al. Hyperfractionated radiotherapy and concomitant cisplatin for locally advanced laryngeal and hypopharyngeal carcinomas: Final results of a Single-Institutional program. Am J Clin Oncol. 2003;26:550-7
35. Ang KK, Harris J, Garden AS, et al. Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas: Preliminary results of a phase II trial of the RTOG (99-14) [abstract]. Int J Radiat Oncol Biol Phys. 2002;54 (Supl 0):71.
36. Antonadou D, Pepelasi M, Synodinou M, et al. Prophylactic use of amifostin to prevent radiochemotherapy-in-duced mucositis and xerostomy in head and neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:739-47
37. Vokes EE, Pajak TF. Enhancing the therapeutic index of concomitant chemoradiotherapy for head and neck cancer. Ann Oncol. 1998;9:471-4.
38. Eisbruch A, Shewach D, Bradford C, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. JCO. 2001;19:792-9.
39. Sunwoo J, Herscher L, Kroog G, et al. Concurrent pacli-taxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol. 2001;19:800-11.
40. Robert F, Ezekiel M, Spencer S, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuxi-mab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001; 19:3234-43.
41. Temam S, Flahaut A, Perie S, et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2000; 18:385-90.
42. Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucle-otide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000;404: 42-9.
43. Pruneri G, Pignataro L, Carboni N, et al. Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p51 and p27 in laryngeal cancer. J Clin Oncol. 1999;17: 3150-9.
44. Veltmant JA, Bot FJ, Huynen FC, et al. Chromosome instability as an indicator of malignant progression in laryngeal mucosa. J Clin Oncol. 2000;18:1644-51.
45. Falck J, Mailand N, Syljuasen R, et al. The ATM-Chk2-Cdc checkpoint parway guards against radioresistant DNA syntesis. Nature. 2001;410:842-7
46. Aaronson NK, Ahmedzai S, Bergman B, et al; The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-76.
47. Bjordal K, Hammerlid E, Ahlner-Elmqvist M, et al. Quality of life in head and neck patients: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol. 1999;17:1008-19.